E. Bah, M. P. Carrieri, and P. Hainaut, 20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia, West Africa. PLoS One, vol.8, p.75775, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01261767

L. A. Torre, F. Bray, and R. L. Siegel, Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012.

, Some traditional herbal medicines, some mycotoxins, naphthalene and styrene: this publication represents the views and expert opinions of an IARC working group on the evaluation of carcinogenic risks to hHumans, which met in Lyon, Lyon : IARC, vol.590, pp.12-19, 2002.

G. D. Kirk, O. A. Lesi, and M. Mendy, 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma, Oncogene, vol.24, pp.5858-67, 2005.

M. H. Kuniholm, O. A. Lesi, and M. Mendy, Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect, vol.116, pp.1553-1560, 2008.

Y. F. Liaw, J. Sung, and W. C. Chow, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, vol.351, pp.1521-1552, 2004.

M. C. Robotin, M. Q. Kansil, and J. George, Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation, BMC Health Serv Res, vol.10, p.215, 2010.

P. M. Lopez, A. Villanueva, and J. M. Llovet, Systematic review: evidence-based management of hepatocellular carcinoma: an updated analysis of randomized controlled trials, Aliment Pharmacol Ther, vol.23, pp.1535-1582, 2006.

E. Easl, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, vol.56, pp.908-951, 2012.

J. D. Yang, E. A. Mohamed, and A. Aziz, Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium, Lancet Gastroenterol Hepatol, vol.2, pp.103-114, 2017.

Y. Shimakawa, Y. Takao, and S. T. Anderson, The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia, West Africa, Palliat Med, vol.29, pp.184-189, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-02875314

Y. Shimakawa and M. Lemoine, Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa, Lancet Gastroenterol Hepatol, vol.2, p.393, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01740756

H. F. Njai, Y. Shimakawa, and B. Sanneh, Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa, J Clin Microbiol, vol.53, pp.1156-63, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-02875309

N. G. Ladep, A. C. Dona, and M. R. Lewis, Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans, Hepatology, vol.60, pp.1291-301, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-02875319

E. Keane, A. L. Funk, and Y. Shimakawa, Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa, Aliment Pharmacol Ther, vol.44, pp.1005-1022, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-02875274

M. Lemoine, Y. Shimakawa, and R. Njie, Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the prevention of liver fibrosis and cancer in Africa (PROLIFICA) study, Lancet Glob Health, vol.4, pp.559-67, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-02875279

Y. Shimakawa, D. Pourette, and L. Bainilago, Improving communication about viral hepatitis in Africa, Lancet Infect Dis, vol.17, pp.688-697, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01567827

A. Lok and B. J. Mcmahon, Chronic hepatitis B: update 2009, Hepatology, vol.50, pp.1-662, 2009.

P. Marcellin, F. Zoulim, and C. Hézode, Effectiveness and safety of Tenofovir Disoproxil Fumarate in chronic hepatitis B: A 3-year, prospective, real-world study in France, Dig Dis Sci, vol.61, pp.3072-83, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01812701

S. Nayagam, M. Thursz, and E. Sicuri, Requirements for global elimination of hepatitis B: a modelling study, Lancet Infect, vol.16, pp.1399-408, 2016.

S. Nayagam, L. Conteh, and E. Sicuri, Cost-effectiveness of communitybased screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis, Lancet Glo Health, vol.4, pp.568-578, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-02875275

S. Ghosh, A. Sow, and C. Guillot, Implementation of an in-house quantitative real-time polymerase chain reaction method for hepatitis B virus quantification in West African countries, J Viral Hepat, vol.23, pp.897-904, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01792611

Y. Ni, J. Sonnabend, and S. Seitz, The pre-S2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-proteinconnected virus assembly, J Virol, vol.84, pp.3879-88, 2010.

Y. H. Hsieh, Y. Y. Chang, and I. J. Su, Hepatitis B virus pre-S 2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis: HBV pre-S2 mutant LHBS, Nijmegen breakage and importin ?1, J Pathol, vol.236, pp.337-384, 2015.

, World health organization. Global hepatitis report, 2017.

, European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection, J Hepatol, vol.57, pp.167-85, 2012.

J. Ferlay, I. Soerjomataram, and R. Dikshit, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012, Int J Cancer, vol.136, pp.359-86, 2015.

I. Graber-stiehl, The silent epidemic killing more people than HIV, malaria or TB, Nature, vol.564, p.24, 2018.

C. F. Kiire, The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa, Gut, vol.38, pp.5-12, 1996.

A. Schweitzer, J. Horn, and R. T. Mikolajczyk, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between, Lancet, vol.386, pp.1546-55, 1965.

M. Lemoine, Y. Shimakawa, and R. Goldin, P1019 validation and comparison of non-invasive markers of liver fibrosis in West-African patients with chronic hepatitis B living in the Gambia, J Hepatol, vol.60, pp.414-419, 2014.

M. Lemoine, Y. Shimakawa, and S. Nayagam, The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa, Gut, vol.65, pp.1369-76, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-02875304

M. Shariff, N. G. Ladep, and I. J. Cox, Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population, J. Proteome Res, vol.9, pp.1096-103, 2010.

Y. Shimakawa, R. Njie, and G. Ndow, Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa, Journal of Hepatology, vol.69, pp.776-84, 2018.
URL : https://hal.archives-ouvertes.fr/pasteur-01896895

M. Lemoine, Y. Shimakawa, and R. Njie, Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in the Gambia, Aliment Pharmacol Ther, vol.39, pp.188-96, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-02875331